International Journal of Reproductive BioMedicine

Published date: Sep 21 2025

Journal Title: International Journal of Reproductive BioMedicine

Issue title: International Journal of Reproductive BioMedicine (IJRM): Volume 23, Issue No. 8

Pages: 637 – 646

DOI: 10.18502/ijrm.v23i8.19813

Gholamreza Fotoohi-ArdakaniDepartment of Molecular Medicine, School of Advanced Technologies in Medicine, Shahid Sadoughi University of Medical Sciences, Yazd

Nasrin GhasemiAbortion Research Center, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd

Azam Hassanpour DehnaviDepartment of Anatomical Sciences, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd

Ali DadbinpourDepartment of Medical Genetics, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd

Marzieh LotfiM.lotfi@ssu.ac.irDepartment of Molecular Medicine, Abortion Research Center, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd

Background: Platelet-rich plasma (PRP), a new therapeutic technique, has the potential to regenerate failing ovarian tissue and alleviate symptoms in patients with premature ovarian failure (POF).

Objective: This study examined the effect of different platelet concentrations on ovarian function, investigated the apoptosis genes B-cell lymphoma 2 (BCL-2) and Bcl-2-associated X protein, and the differentiation gene octamer-binding transcription factor 4.

Materials and Methods: In this experimental study, 30 female Syrian mice (8–10 wk, 25–30 gr) were randomly divided into 5 groups (n = 6/each): 1) normal control, 2) POF + phosphate buffered saline, 3) POF + PRP 0.25 ml/kg, 4) POF + PRP 0.5 ml/kg, and 5) POF + PRP 1 ml/kg. The cyclophosphamide was used to create a mouse model of POF. After 2 wk from injection of PRP and phosphate buffered saline, ovaries were removed for histological and molecular analysis.

Results: The distribution of different follicle types in the POF + PRP group was the same as that of the control group, according to a morphometric study. Bcl-2-associated X protein gene expression was significantly reduced in the groups that received PRP (p < 0.001). BCL-2 and octamer-binding transcription factor 4 gene expression was also increased in the PRP groups (p < 0.05), but the gene expression was different in different platelet concentrations.

Conclusion: The results showed that PRP can be effective in POF, but different dosages of PRP can have different effects on the recovery of ovarian.

Keywords: Platelet-rich plasma, Premature ovarian failure, Cyclophosphamide

[1] El Bakly W, Medhat M, Shafei M, Tash R, Elrefai M, Shoukry Y, et al. Optimized platelet rich plasma releasate (O-rPRP) repairs galactosemia-induced ovarian follicular loss in rats by activating mTOR signaling and inhibiting apoptosis. Heliyon 2020; 6: e05006.

[2] Petryk N, Petryk M. Ovarian rejuvenation through platelet-rich autologous plasma (PRP)-a chance to have a baby without donor eggs, improving the life quality of women suffering from early menopause without synthetic hormonal treatment. Reprod Sci 2020; 27: 1975–1982.

[3] Vogt EC, Bratland E, Berland S, Berentsen R, Lund A, Bjornsdottir S, et al. Improving diagnostic precision in primary ovarian insufficiency using comprehensive genetic and autoantibody testing. Hum Reprod 2024; 39: 177–189.

[4] Kim J, You S. Extended adverse effects of cyclophosphamide on mouse ovarian function. BMC Pharmacol Toxicol 2021; 22: 3.

[5] Zhang S, Liu Q, Chang M, Pan Y, Yahaya BH, Liu Y, et al. Chemotherapy impairs ovarian function through excessive ROS-induced ferroptosis. Cell Death Dis 2023; 14: 340.

[6] Sadeghi S, Mosaffa N, Huang B, Ramezani Tehrani F. Protective role of stem cells in POI: Current status and mechanism of action, a review article. Heliyon 2023; 10: e23271.

[7] Kim HK, Kim TJ. Current status and future prospects of stem cell therapy for infertile patients with premature ovarian insufficiency. Biomolecules 2024; 14: 242.

[8] Ferrari AR, Cortrezzi S, Junior EB, Braga D, se Souza MCB, Antunes RA. Evaluation of the effects of platelet-rich plasma on follicular and endometrial growth: A literature review. JBRA Assist Reprod 2021; 25: 601–607.

[9] Subiran Adrados C, Cadenas J, Polat SL, Tjader AS, Blanche P, Kristensen SG. Exploring the potential use of platelet rich plasma (PRP) from adult and umbilical cord blood in murine follicle culture. Reprod Biol 2024; 24: 100851.

[10] Wang X, Li J, Lu W, Gao F, Zhang S, Li J. Therapeutic roles of platelet-rich plasma to restore female reproductive and endocrine dysfunction. Front Endocrinol (Lausanne) 2024; 15: 1374382.

[11] Hosseini L, Shirazi A, Naderi MM, Shams-Esfandabadi N, Borjian Boroujeni S, Sarvari A, et al. Platelet-rich plasma promotes the development of isolated human primordial and primary follicles to the preantral stage. Reprod Biomed Online 2017; 35: 343–350.

[12] Cecerska-Heryc E, Goszka M, Serwin N, Roszak M, Grygorcewicz B, Heryc R, et al. Applications of the regenerative capacity of platelets in modern medicine. Cytokine Growth Factor Rev 2022; 64: 84–94.

[13] Li W, Xu J, Deng D. The effect of ovarian response parameters and the synergistic effect of assisted reproduction of poor ovarian response treated with platelet rich plasma: Systematic review and meta-analysis. BMC Womens Health 2024; 24: 263.

[14] Jiang X-L, Tai H, Kuang J-S, Zhang J-Y, Cui S-C, Lu Y-X, et al. Jian-Pi-Yi-Shen decoction inhibits mitochondria-dependent granulosa cell apoptosis in a rat model of POF. Aging (Albany NY) 2022; 14: 8321–8345.

[15] Rowley JE, Rubenstein GE, Manuel SL, Johnson NL, Surgnier J, Kapitsinou PP, et al. Tissue-specific fixation methods are required for optimal in situ visualization of hyaluronan in the ovary, kidney, and liver. J Histochem Cytochem 2020; 68: 75–91.

[16] Veitia RA. Primary ovarian insufficiency, meiosis and DNA repair. Biomed J 2020; 43: 115–123.

[17] Wallace WHB, Kelsey TW. Primary ovarian insufficiency prediction in adult survivors of childhood cancer: Model concerns. Lancet Oncol 2024; 25: e57.

[18] Jiang Y, Zhang Z, Cha L, Li L, Zhu D, Fang Z, et al. Resveratrol plays a protective role against premature ovarian failure and prompts female germline stem cell survival. Int J Mol Sci 2019; 20: 3605.

[19] Fraidakis M, Giannakakis G, Anifantaki A, Skouradaki M, Tsakoumi P, Bitzopoulou P, et al. Intraovarian platelet-rich plasma injections: Safety and thoughts on efficacy based on a single centre experience with 469 women. Cureus 2023; 15: e38674.

[20] Barad DH, Albertini DF, Molinari E, Gleicher N. Preliminary report of intraovarian injections of autologous platelet-rich plasma (PRP) in extremely poor prognosis patients with only oocyte donation as alternative: A prospective cohort study. Hum Reprod Open 2022; 2022: hoac027.

[21] Rossi L, Ranalletta M, Pasqualini I, Zicaro JP, Paz MC, Camino P, et al. Substantial variability in platelet-rich plasma composition is based on patient age and baseline platelet count. Arthrosc Sports Med Rehabil 2023; 5: e853-e858.

[22] Zheng C, Zhu Q, Liu X, Huang X, He C, Jiang L, et al. Effect of platelet-rich plasma (PRP) concentration on proliferation, neurotrophic function and migration of Schwann cells in vitro. J Tissue Eng Regen Med 2016; 10: 428–436.

[23] Vali S, Saso S, Bracewell Milnes T, Nicopoullos J, Thum M-Y, Smith JR, et al. The clinical application of platelet-rich plasma in the female reproductive system: A narrative review. Life (Basel) 2023; 13: 2348.

[24] Ozcan P, Takmaz T, Tok OE, Islek S, Yigit EN, Ficicioglu C. The protective effect of platelet-rich plasma administrated on ovarian function in female rats with Cy-induced ovarian damage. J Assist Reprod Genet 2020; 37: 865–873.

[25] Seckin S, Ramadan H, Mouanness M, Kohansieh M, Merhi Z. Ovarian response to intraovarian platelet-rich plasma (PRP) administration: Hypotheses and potential mechanisms of action. J Assist Reprod Genet 2022; 39: 37–61.

[26] Dehghan Manshadi E, Rezvani ME, Hassanpour A, Zare Mehrgerdi F, Lotfi M. Reduction of Apoptotic gene expression by platelet-rich plasma in a mouse model of premature ovarian failure. Biomed Res Ther 2024; 11: 6447–6456.

[27] Ahmadian Sh, Sheshpari S, Pazhang M, Bedate AM, Beheshti R, Mesgari Abbasi M, et al. Intra-ovarian injection of platelet-rich plasma into ovarian tissue promoted rejuvenation in the rat model of premature ovarian insufficiency and restored ovulation rate via angiogenesis modulation. Reprod Biol Endocrinol 2020; 18: 78.

[28] Yuan L, Huang W, Bi Y, Chen S, Wang X, Li T, et al. G-CSF-mobilized peripheral blood mononuclear cells combined with platelet-rich plasma restored the ovarian function of aged rats. J Reprod Immunol 2023; 158: 103953.

[29] Yahyavi Y, Karimi A, Ebrahimi-Kalan A, Ramezani F, Hasanzadeh M, Yousefi S, et al. Assessment of platelet-rich plasma (PRP) effects on the proliferation and apoptosis of cyclophosphamide-induced damage in human granulosa cells. Pharmaceutical Sci 2024; 30: 204–214.

[30] Bakhmet EI, Tomilin AN. Key features of the POU transcription factor Oct4 from an evolutionary perspective. Cell Mol Life Sci 2021; 78: 7339–7353.